Immunovant Inc (NASDAQ: IMVT) is a clinical-stage biopharmaceutical company focused on developing treatments for immunological diseases. The company generates no product revenue, funding operations entirely through equity financing, including underwritten offerings and private placements. Net cash used in operating activities was $407.3 million in FY2026 (year ended March 31, 2026), $375.9 million in FY2025, and $214.2 million in FY2024, reflecting a growing cash burn as clinical programs advance. Financing activities provided $595.8 million in FY2026, $454.5 million in FY2025, and $472.4 million in FY2024. The company has an accumulated deficit on its balance sheet as of March 31, 2026, and relies on contract research organizations to conduct clinical trials. Immunovant has a relationship with Roivant Sciences Ltd., reflected as a liability on its balance sheet. The company operates subject to extensive pharmaceutical pricing, data privacy, and regulatory requirements across the U.S., European Union, and United Kingdom.

Revenue model

No product revenue as of FY2026 (year ended March 31, 2026). Operations are funded through equity capital raises, including underwritten public offerings and private placements. Cash provided by financing activities totaled $595.8 million in FY2026.

Products and services

Clinical-stage product candidates in immunology. No approved or commercialized products are identified in the filing excerpts.

Customers and end markets

No commercial customers as of the filing date (10-K filed 2026-05-20). End market is immunological disease treatment, subject to pharmaceutical pricing regulation and reimbursement constraints from Medicare, Medicaid, and private payors.

Value-chain role

Drug developer with no manufacturing or commercial operations disclosed. Relies on contract research organizations for clinical trial execution. Subject to FDA and international regulatory approval processes before any commercialization.

Geographic exposure

Operates clinical trials in the United States, European Economic Area, and United Kingdom, based on references to FDA, EU GDPR, and UK GDPR compliance obligations in the FY2026 10-K filing.

Source: SEC 10-K, filed 2026-05-20

Industry: Biological Products, (No Diagnostic Substances) Peers: Adicet Bio Inc Stoke Therapeutics Inc Century Therapeutics Inc G1 Therapeutics, Inc. Janux Therapeutics Inc Kezar Life Sciences Inc Kinnate Biopharma Inc. PMV Pharmaceuticals Inc Vanda Pharmaceuticals Inc